At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRME Prime Medicine, Inc.
Post-Market Trading 11-07 17:30:39 EST
4.10
+0.00
0.00%
盘后4.12
+0.02+0.53%
16:56 EST
High4.24
Low4.06
Vol711.23K
Open4.10
D1 Closing4.10
Amplitude4.39%
Mkt Cap492.13M
Tradable Cap237.42M
Total Shares120.03M
T/O2.93M
T/O Rate1.23%
Tradable Shares57.91M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Prime Medicine treatment of retinal dystrophy granted orphan designation
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.